Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00541671 · ClinicalTrials.gov registry record · NA
Prevention of Narcotic-Induced Nausea
A NA study, sponsored by Christiana Care Health Services.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00541671: Clinical Trial NA study, sponsored by Christiana Care Health Services.
NCT00541671 is a NA study that was terminated before completion, run by Christiana Care Health Services. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00541671, a NA study, was terminated before completion, sponsored by Christiana Care Health Services.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants.
Interventions
- DRUG Saline
- DRUG Phenergan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-11 |
| Phase | NA |
Why NCT00541671 stopped before completion
NCT00541671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00541671 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00541671 about?
NCT00541671 is a clinical study titled "Prevention of Narcotic-Induced Nausea". We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking t...
What is the current status of trial NCT00541671?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2007-02. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00541671?
The interventions under investigation include: Saline (DRUG), Phenergan (DRUG).
Who is sponsoring clinical trial NCT00541671?
This trial is sponsored by Christiana Care Health Services, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00541671's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia